Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro

Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 and to combat this pandemic. Manipulation of epigenetic machinery to influence viral infectivity of host cells is a relatively unexplored area. The bromodomain and extraterminal...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Dean Gilham, Audrey L. Smith, Li Fu, Dalia Y. Moore, Abenaya Muralidharan, St. Patrick M. Reid, Stephanie C. Stotz, Jan O. Johansson, Michael Sweeney, Norman C. W. Wong, Ewelina Kulikowski, Dalia El-Gamal
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2021-04-01
סדרה:	Biomedicines
נושאים:	COVID-19 SARS-CoV-2 BET proteins apabetalone angiotensin-converting enzyme 2 (ACE2)
גישה מקוונת:	https://www.mdpi.com/2227-9059/9/4/437
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!